Patricia Martin‐Regueira

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial

Courtney D. DiNardo, Andre C. Schuh, Eytan M. Stein et al. · The Lancet Oncology · 2021 · 191 citations

Medicine, Hematology, Oncology +11

Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study

Neil P. Shah, Valentín García‐Gutiérrez, Antonio Jiménez‐Velasco et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2019 · 150 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +8

Enasidenib vs conventional care in older patients with late-stage mutant-<i>IDH2</i> relapsed/refractory AML: a randomized phase 3 trial

Stéphane de Botton, Pau Montesinos, Andre C. Schuh et al. · Blood · 2022 · 115 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma

Philippe Armand, Ann Janssens, Giuseppe Gritti et al. · Blood · 2020 · 94 citations · Full text

Medicine, Immunology, Oncology +12

Hematopoietic cell transplantation in acute lymphoblastic leukemia: better long term event-free survival with conditioning regimens containing total body irradiation.

Enrique Granados, Rafael de la Cámara, L Madero et al. · PubMed · 2000 · 65 citations

Medicine, Hematology, Oncology +16